



TALIGEN RECEIVES BIOSCIENCE COMPANY OF THE YEAR AWARD

CSO HOLERS HONORED WITH LIFETIME ACHIEVEMENT AWARD

- 7th Annual University of Colorado Technology Transfer Awards -

Cambridge, MA, June 23, 2010 – Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, today announced that it has been selected as the Bioscience Company of the Year by the University of Colorado with its 7th Annual Technology Transfer Awards in recognition of its leadership position in developing a pipeline of novel protein therapeutics that modulate the complement system to treat a wide range of inflammatory diseases. In addition, V. Michael Holers, Ph.D., Taligen’s Co-Founder and Chief Scientific Officer and a Professor at the University of Colorado, Denver, was honored with the Pinnacle of Inventorship Lifetime Achievement Award for his unparalleled career as one of the world’s leading experts in complement biology.

“We are pleased to have been honored by the University of Colorado for our pipeline of novel tissue-targeted complement inhibitors as they offer a truly unique approach to treating a broad array of genetic and inflammatory diseases,” said Abbie Celniker, Ph.D., President and CEO of Taligen. “Taligen’s progress and proprietary know-how is based on Dr. Holers’ groundbreaking research in complement system biology and, in particular, the complement alternative pathway. We are pleased that Dr. Holers is being recognized by the University of Colorado for his outstanding contributions in the field. Indeed, we are honored to have him as a member of the Taligen senior leadership team as he is a critical part of our goal to make a difference in the lives of patients afflicted with complement mediated diseases.”

About Taligen Therapeutics

Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify,

target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. For additional information about the Company, please visit www.taligetherapeutics.com.

Contact:

Gina Nugent

The Yates Network

Tel: 617-460-3579

###